William Schmidt, Ph.D., Senior Vice President, Clinical Development

Oct. 12 | 11:45am | AVROBIO Ballroom

Seoul, Korea

(KOSDAQ: 084990)

In-person Presentation

Helixmith is a gene therapy company developing new and innovative biopharmaceuticals based upon its proprietary scientific platform technology to address unmet medical needs. Currently, the company is focused on developing the plasmid DNA-based drug, Engensis, at various clinical stages in the U.S. and Korea for neurological diseases including, but not limited to, painful diabetic peripheral neuropathy, diabetic foot ulcers, amyotrophic lateral sclerosis, and Charcot-Marie-Tooth disease. The company also has an early phase pipeline, including a CAR T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases.


By using this website you agree to accept our Privacy Policy and Terms & Conditions